EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjunctive Brexpiprazole in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Study

Jia Yang Poi, Chong Guan Ng, Julian Joon Ip Wong, David Ming Gui Tan

Pharmacoepidemiology · 06.11.2026 · 5 (4) · 48

DOI: 10.3390/pharma5040048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 06.11.2026. Verfasst von Jia Yang Poi und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H. Lundbeck A/S.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated the effects of adjunctive brexpiprazole in adult patients with Major Depressive Disorder (MDD) who experienced an inadequate response to antidepressant therapy.

Methods

This 12-week, multicentre, naturalistic, prospective observational study enrolled 60 adults with MDD and an inadequate response to at least two antidepressant treatments. Depressive symptoms, anxiety, clinician-rated illness severity and improvement, functioning, and quality of life were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Clinical Global Impressions—Severity (CGI-S) and —Improvement (CGI-I), Sheehan Disability Scale (SDS), and World Health Organization Quality of Life—Brief Version (WHOQOL-BREF). GAD-7 was assessed only at baseline and week 12. Inferential analyses used complete observations without imputation.

Results

Fifty participants (83.3%) completed week 12 and contributed to the principal symptom analyses. Mean PHQ-9 scores decreased from 16.68 ± 5.64 to 11.50 ± 7.30, and GAD-7 scores from 13.32 ± 4.98 to 9.80 ± 5.63 (both p < 0.001). At week 12, PHQ-9 response and remission rates among these 50 participants were 38.0% and 22.0%; corresponding GAD-7 rates were 34.0% and 14.0%. Mean CGI-S decreased from 5.00 ± 1.16 to 3.52 ± 1.79 (p < 0.001); mean week-12 CGI-I was 2.44 ± 1.22. In 43 participants with all three SDS domains recorded at both visits, mean total SDS decreased from 16.79 ± 7.26 to 11.74 ± 8.65 (p < 0.001). Physical, psychological, and social relationship WHOQOL-BREF domains improved, whereas the overall quality-of-life item did not change significantly.

Conclusions

In clinical practice, adjunctive brexpiprazole was associated with early improvement in depressive symptoms and improvements in anxiety symptoms, illness severity, psychosocial functioning, and quality-of-life domains.

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Poi, J. Y., Ng, C. G., Wong, J. J. I., & Tan, D. M. G. (2026). Adjunctive Brexpiprazole in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Study. Pharmacoepidemiology, 5(4), 48. https://doi.org/10.3390/pharma5040048

Vancouver

Poi JY, Ng CG, Wong JJI, Tan DMG. Adjunctive Brexpiprazole in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Study. Pharmacoepidemiology. 2026;5(4):48. doi:10.3390/pharma5040048

BibTeX
@article{Poi2026,
  author = {Poi, Jia Yang and Ng, Chong Guan and Wong, Julian Joon Ip and Tan, David Ming Gui},
  title = {Adjunctive Brexpiprazole in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Study},
  journal = {Pharmacoepidemiology},
  year = {2026},
  volume = {5},
  number = {4},
  pages = {48},
  doi = {10.3390/pharma5040048}
}
Kostenlos starten →